Akoya Biosciences, Inc.

As of November 8, 2021, Akoya Biosciences, Inc. is considered risky due to negative valuation ratios, including a Price to Book Value of -9.82 and an EV to EBITDA of -3.70, alongside a troubling -80.86% ROCE, which highlights its overvaluation and poor performance compared to peers and the S&P 500.

As of November 8, 2021, Akoya Biosciences, Inc. is considered overvalued and risky, with concerning financial metrics such as a Price to Book Value of -9.82 and a year-to-date return of -43.67%, significantly underperforming the S&P 500.

As of June 20, 2025, Akoya Biosciences, Inc. shows a neutral technical stance with mixed signals, indicating a shift from mildly bearish to sideways, as various indicators present both bullish and bearish trends without strong momentum.

Akoya Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $17 million and a net loss of $16 million as of March 2025. The company has a market cap of $62.44 million and does not pay dividends.

As of Jun 18, Akoya Biosciences, Inc. has a market capitalization of 62.44 million, with net sales of 79.95 million and a net profit of -47.53 million over the last four quarters. Shareholder's funds are 7.59 million, and total assets are 125.00 million.